Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Manufacturer: Outlook Therapeutics
Regulatory submission: BLA approved July 2026
Launch: Anticipated before the end of 2026
Last updated: September 28, 2026

Section

Product information and disease description Place of product in therapy

Disease description

45 evidence topics · 16 sources

Definition and etiology6 evidence topics · 3 sources
Epidemiology8 evidence topics · 4 sources
Natural history, survival, and mortality4 evidence topics · 2 sources
Pathophysiology4 evidence topics · 3 sources
Diagnosis4 evidence topics · 4 sources
Clinical presentation - signs and symptoms3 evidence topics · 2 sources
Long-term morbidity4 evidence topics · 3 sources
Burden of Neovascular age-related macular degeneration12 evidence topics · 5 sources